A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-07. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Drugs active in microgram range, most notably LSD, are commonly distributed illicitly on blotting paper. A liquid solution of the drug is applied to the blotting paper, which commonly is perforated into individual doses and artfully decorated with what is known as blotter art. Vanity blotter is blotter art that has not been exposed to LSD and is usually sold as a collectible, although inevitably much of this art ends up in illegal distribution. The artwork is printed onto blotter paper and then sometimes perforated into tiny squares or "tabs" which can be torn or cut apart. Most blotter art designs have grid lines as part of the design to either aid in perforation or to be left as a cutting grid. Blotter as a drug delivery method allows for easy dosing of potent substances, and easy sublingual administration of drugs which has made it increasingly popular as a preparation for other potent drugs, including 25I-NBOMe and alprazolam. Plain white LSD blotter without artwork is commonly referred to as “WoW” (White on White) and is usually not perforated but rather gridded with a pen and sometimes laid on common watercolour paper.
Russia claimed to have taken the village of Keramik in Donetsk Oblast. Ukraine claimed to have shot down a Russian Su-25 fighter jet over Donetsk Oblast. Two people were killed by Russian bombing in Vovchansk. One person was killed in a missile strike in Sumy. In Russia, drones were reported over Belgorod and Kursk Oblasts. Several projectiles were shot down but debris left "several dozen" private homes, mostly smashed windows, and cars damaged. Russian officials subsequently claimed that five people were killed and nine injured by drone strikes in Belgorod, Kursk and Donetsk Oblasts. A Russian Iskander missile struck a Ukrainian forward arming and refuelling point in Pavlohrad, Donetsk Oblast. Two Mi-24s and a Mi-17 helicopter which had just landed were seriously damaged. Video was released of a Russian drone striking a Ukrainian Buk-M1 missile system which appeared to have been fitted with US made RIM-7 Sea Sparrow missiles instead of the original 9M38 missiles.
=== OMICS Genomics === Provides DNA sequencing and DNA fragmentation analysis services. Uses Sanger sequencing and next-generation sequencing (NGS) on Illumina MiSeq platforms. Offers quality control for DNA, RNA, and NGS libraries using instrumentation such as spectrophotometers, fluorometers, and Bioanalyzer systems.
Rainwater will also be harvested at prospective locations along the expressway to ensure water availability. The expressway will connect several tourism circuits offering eco, pilgrim, and heritage tourism, which will include wildlife resorts, tiger safaris, museums, sightseeing destinations, and theme-based retail outlets. The expressway is a 6 lane (with paved and unpaved shoulders on both sides) access-controlled super communication expressway comprising a total width of 120 m (90 m in hilly terrain) with a central median of 22.5 m. The expressway will be the country's largest 'Greenfield' route alignment, including 65 flyovers/viaducts, 24 interchanges, 6 tunnels, 400+ vehicular, 300+ pedestrian underpasses, and cattle underpasses at strategic locations.
Sources: en.wikipedia.org
== Discovery == In 1836 or 1837, German peasant Peter Kasten discovered diatomaceous earth (German: Kieselgur) when sinking a well on the northern slopes of the Haußelberg hill, on Lüneburg Heath in North Germany. The extraction site on Lüneburg Heath from 1863 to 1994 was Neuohe, while the storage sites were:
The strong homology seen in the insulin sequence of diverse species suggests that it has been conserved across much of animal evolutionary history. The C-peptide of proinsulin, however, differs much more among species; it is also a hormone, but a secondary one. Insulin is produced and stored in the body as a hexamer (a unit of six insulin molecules), while the active form is the monomer. The hexamer is about 36000 Da in size. The six molecules are linked together as three dimeric units to form symmetrical molecule. An important feature is the presence of zinc atoms (Zn2+) on the axis of symmetry, which are surrounded by three water molecules and three histidine residues at position B10. The hexamer is an inactive form with long-term stability, which serves as a way to keep the highly reactive insulin protected, yet readily available. The hexamer-monomer conversion is one of the central aspects of insulin formulations for injection. The hexamer is far more stable than the monomer, which is desirable for practical reasons; however, the monomer is a much faster-reacting drug because diffusion rate is inversely related to particle size. A fast-reacting drug means insulin injections do not have to precede mealtimes by hours, which in turn gives people with diabetes more flexibility in their daily schedules. Insulin can aggregate and form fibrillar interdigitated beta-sheets. This can cause injection amyloidosis, and prevents the storage of insulin for long periods.
Doses… were subcutaneously injected into young dogs and rabbit… with the following general results… great prostration, fear, and sleepiness speedily following the administration, the eyes being sensitive, and pupils constrict, considerable salivation being produced in dogs, and a slight tendency to vomiting in some cases, but no actual emesis. Respiration was at first quickened, but subsequently reduced, and the heart's action was diminished and rendered irregular. Marked want of coordinating power over the muscular movements, and loss of power in the pelvis and hind limbs, together with a diminution of temperature in the rectum of about 4°.
Sources: en.wikipedia.org
Strontium carbonate and other strontium salts are added to fireworks to give a deep red colour. This same effect identifies strontium cations in the flame test. Fireworks consume about 5% of the world's production. Strontium carbonate is used in the manufacturing of hard ferrite magnets. Strontium chloride is sometimes used in toothpastes for sensitive teeth. One popular brand includes 10% total strontium chloride hexahydrate by weight. Small amounts are used in the refining of zinc to remove small amounts of lead impurities. The metal itself has a limited use as a getter, to remove unwanted gases in vacuums by reacting with them, although barium may also be used for this purpose. The ultra-narrow optical transition between the [Kr]5s2 1S0 electronic ground state and the metastable [Kr]5s5p 3P0 excited state of 87Sr is one of the leading candidates for the future re-definition of the second in terms of an optical transition as opposed to the current definition derived from a microwave transition between different hyperfine ground states of 133Cs. Current optical atomic clocks operating on this transition already surpass the precision and accuracy of the current definition of the second.
== Causes == In premenopausal women, adnexal masses include ovarian cysts, ectopic (tubal) pregnancies, benign or malignant tumors, endometriomas, polycystic ovaries, and tubo-ovarian abscess. The most common causes for adnexal masses in premenopausal women include follicular cysts and corpus luteum cysts. Abscesses can form as a complication of pelvic inflammatory disease. In postmenopausal women, adnexal masses may be caused by cancer, fibroids, fibromas, or diverticular abscesses.
== History == The glyoxylate cycle was discovered in 1957 at the University of Oxford by Sir Hans Kornberg and his mentor Hans Krebs, resulting in a Nature paper Synthesis of Cell Constituents from C2-Units by a Modified Tricarboxylic Acid Cycle. Kornberg and Krebs utilized isotopic labeling with C-14 acetate to demonstrate that in the glyoxylate pathway, the acetate is incorporated into the succinate intermediate while bypassing the decarboxylation steps of the TCA cycle. Their results from isotopic experiments laid the foundation for the alternative glyoxylate cycle and explained how plants as well as microorganisms convert two-carbon molecules into carbohydrates. Following this discovery, in 1967 Breidenbach and Beevers discovered that there is a specialized organelle in castor bean (Ricinus communis), glyoxysomes, which are specialized peroxisomes where the glyoxylate cycle enzymes are found and where the cycle takes place in plants.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.